|
|operating_income= $ 299 million (2014)〔 |net_income= $ 267 million (2014)〔(【引用サイトリンク】title=Boston Scientific 2011 Annual Report, Form 10-K, Filing Date Feb 17, 2012 )〕 |assets= $ 16.83 billion (2014)〔 |equity= $ 16.83 billion (2014)〔 |num_employees = 24,000 (December 2011)〔 | homepage = (www.bostonscientific.com )| }} The Boston Scientific Corporation (abbreviated BSC) is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is well known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. Boston Scientific's main competitors are Johnson and Johnson, Medtronic, St. Jude Medical, and the Abbott Vascular division of Abbott Laboratories. == History == Boston Scientific was formed June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine.〔(【引用サイトリンク】 title= About Us - History )〕 The company went public through an IPO on May 19, 1992.〔 The Taxus Stent was approved in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.〔 On April 21, 2006, the company acquired longtime competitor Guidant for $27.2 billion. The former Guidant was split between BSC and Abbott Laboratories.〔(【引用サイトリンク】 date = April 21, 2006 ) Boston Scientific's press release on the acquisition.〕 Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.〔(【引用サイトリンク】 date = August 5, 2008 )〕 In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others.〔Bernton, Hal, "Army Whistle-Blower Fights To Clear Name", ''Seattle Times'', 14 August 2011, p. 1.〕 In March 2015, the company announced it would acquire Endo International Plcs urology business for at least $1.6 billion, expanding the company's health and prostate treatments. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Boston Scientific」の詳細全文を読む スポンサード リンク
|